Moderna, Inc.

Moderna, Inc. Our mission is to deliver the greatest possible impact to people through mRNA medicines. Moderna is continuously monitoring the safety of its products.

At Moderna, we believe messenger RNA, or mRNA, is the “software of life.” Every cell in the body uses mRNA to provide real-time instructions to make the proteins necessary to drive all aspects of biology, including in human health and disease. Given its essential role, we believe mRNA could be used to create a new category of medicines with significant potential to improve the lives of patients. W

e are pioneering a new class of medicines made of messenger RNA, or mRNA. The potential implications of using mRNA as a drug are significant and far-reaching and could meaningfully improve how medicines are discovered, developed and manufactured. This Moderna page is not the appropriate place to report adverse events (side-effects ) for any products. If you are or someone you know is experiencing a side effects, please reach out to your healthcare professional. We encourage you to report any side effects directly to us at 1‑866‑MODERNA (1‑866‑663‑3762).

11/25/2025

November is Lung Cancer Awareness Month — a moment to recognize the strength of those living with the disease and the urgent need for continued innovation in research.

For Keith Perry, a dedicated triathlete, a lung cancer diagnosis changed everything. Losing his left lung could have ended his active life but instead, it became the start of a new chapter defined by determination and hope.

🎥 Watch Keith’s full story: https://www.modernatx.com/en-US/media-center/all-media/blogs/lung-cancer-awareness-month-meet-keith

10/23/2025

We’re proud to be named a Science Careers Top Employer for the 11th consecutive year! 🏆

This recognition reflects our incredible teams across the globe who turn bold ideas into real-world impact—those who push the boundaries of what’s possible with mRNA science, technology and innovation. Thank you for the curiosity, passion and commitment you bring every day.

Learn more: https://feeds.issuerdirect.com/news-release.html?newsid=7961689400804282&symbol=MRNA

👋💉 This week, Moderna employees hand-delivered the first shipment of our COVID-19 vaccines to a local pharmacy. We’re gr...
08/29/2025

👋💉 This week, Moderna employees hand-delivered the first shipment of our COVID-19 vaccines to a local pharmacy. We’re grateful to the pharmacies, healthcare professionals and partners who make vaccination possible in our communities.

08/19/2025

What constitutes a protein, and how exactly does a protein come together?

Amino acids work together to form intricate chains that fold into functional proteins, each playing their specific role in the body. Watch this video to uncover how it all happens.

For a deeper dive, head to Module 1 on our free 'mRNAs as Medicines' course on Coursera to learn more. https://www.coursera.org/learn/mrnas-as-medicines

Our interns recently spent a morning giving back along the Charles River Esplanade, bringing enthusiasm and teamwork to ...
08/14/2025

Our interns recently spent a morning giving back along the Charles River Esplanade, bringing enthusiasm and teamwork to a day of service in the sun.

From refreshing green spaces to making walkways shine, their dedication was on full display. Whether in the lab, in the community or around the world, we believe in using our time and energy to make a lasting impact.

Thank you to our incredible interns for making a difference!

Today we announced that the European Medicines Agency's Committee for Medicinal Products for Human Use has adopted a pos...
07/25/2025

Today we announced that the European Medicines Agency's Committee for Medicinal Products for Human Use has adopted a positive opinion recommending marketing authorization for an updated formulation of the COVID-19 vaccine Spikevax®, targeting the SARS-CoV-2 variant LP.8.1, for active immunization to prevent COVID-19 caused by SARS-CoV-2 in individuals six months of age and older.

Read more: https://feeds.issuerdirect.com/news-release.html?newsid=7904023827423835&symbol=MRNA

For Jagjit Ludu, joining Moderna meant the chance to think differently and connect science to people in new ways. From l...
07/24/2025

For Jagjit Ludu, joining Moderna meant the chance to think differently and connect science to people in new ways. From launching clinician-focused docu-series to building AI-powered tools for bite-sized learning, he’s reshaping how Medical Affairs engages and informs.

💡 “Being a changemaker means hearing ‘no’ and persisting,” Jagjit shares. His work is proof that creativity and science can move together—and make an impact.

Read more about Jagjit’s journey: https://www.modernatx.com/media-center/all-media/blogs/navigating-growth-embracing-discomfort

We are proud to have earned a top score on Disability:IN's 2025 Disability Index and to be recognized for for the 4th ...
07/16/2025

We are proud to have earned a top score on Disability:IN's 2025 Disability Index and to be recognized for for the 4th year in a row! 🏆

Leading with belonging is essential to helping our people thrive. Thank you Disability:IN for this recognition and for your ongoing leadership in advancing disability inclusion across the business community.

Today we announced that the U.S. Food and Drug Administration has approved the supplemental Biologics License Applicatio...
07/10/2025

Today we announced that the U.S. Food and Drug Administration has approved the supplemental Biologics License Application for Spikevax®, our COVID-19 vaccine, in children 6 months through 11 years of age who are at increased risk for COVID-19 disease. Our COVID-19 vaccine, mRNA-1273, was previously available for pediatric populations under Emergency Use Authorization.

Read more: https://investors.modernatx.com/news/news-details/2025/Moderna-Receives-Full-U-S--FDA-Approval-for-COVID-19-Vaccine-Spikevax-in-Children-Aged-6-Months-Through-11-Years-at-Increased-Risk-for-COVID-19-Disease/default.aspx

This past weekend, our colleagues marched together in both Boston and Warsaw to support one another and celebrate commun...
06/17/2025

This past weekend, our colleagues marched together in both Boston and Warsaw to support one another and celebrate community, connection and the spirit of Pride.

Thank you to the members of the Moderna RaiNbow Alliance, our LGBTQ+ Employee Resource Group, for your leadership and continued support in creating a workplace where everyone can be themselves.

Month is a moment to reflect, celebrate progress and continue working toward a world where everyone can live authentically and feel a true sense of belonging.

Address

325 Binney Street
Cambridge, MA
02142

Telephone

+16176212936

Website

https://www.linkedin.com/company/modernatx/

Alerts

Be the first to know and let us send you an email when Moderna, Inc. posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.

Contact The Business

Send a message to Moderna, Inc.:

Shortcuts

Featured

Share

Category

Our Story

At Moderna, we believe messenger RNA, or mRNA, is the “software of life.”

Every cell in the body uses mRNA to provide real-time instructions to make the proteins necessary to drive all aspects of biology, including in human health and disease. Given its essential role, we believe mRNA could be used to create a new category of medicines with significant potential to improve the lives of patients.

We are pioneering a new class of medicines made of messenger RNA, or mRNA. The potential implications of using mRNA as a drug are significant and far-reaching and could meaningfully improve how medicines are discovered, developed and manufactured.

Since our founding in 2010, we have worked to build the industry's leading mRNA technology platform, the infrastructure to accelerate drug discovery and early development, a rapidly expanding pipeline, and a world-class team. Our pipeline includes development candidates for mRNA-based vaccines and therapies spanning several therapeutic areas, and we have multiple clinical trials underway with other development candidates progressing toward the clinic. In addition, we have numerous discovery programs advancing toward development.